Tests ZG006 in people with advanced neuroendocrine prostate cancer
Tests ZG006 in adults with advanced prostate cancer after standard treatment has failed.
Plain-language title generated from the registry record
Registry title: Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07024277, who can take part
Where in China
- Fudan University Shanghai Cancer CenterShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Trial code
- NCT07024277
- Record updated
- 17 June 2025
- Original description
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.Read full original descriptionShow less
A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Inclusion: Male Participants aged 18 to 80 years (inclusive); Advanced metastatic neuroendocrine prostate cancer; disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity; Measurable disease according to RECIST v1.1 criteria; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion: Known positive test for human immunodeficiency virus (HIV) or hepatitis；; Patients were deemed unsuitable for participating in the study by the investigator for any reason.